Sydney, April 5, 2016 - (ABN Newswire) - iQ3Corp Ltd (ASX:iQ3) is pleased to announce that it has syndicated an investor consortium which include iQ Group Global entities, to enter into a joint venture to develop and commercialise a first in class oncology, novel biologic compound and biomarker. The intellectual property was originally developed at McGill University in Montreal Canada.
In addition, iQ3 has has also been appointed to act as a lead advisor to the consortium and will prepare the joint venture for its next growth phase.
CEO Dr George Syrmalis stated “this is an incredible opportunity which gives Australian Life Science investors access to World Class Biotech assets and creates the opportunity to commercialize a significant novel compound which in this case also involves an accompanying biomarker. This is a strategically significant deal that iQ3 has advised on and signifies the important role we act in Australia’s drive for innovation.
It is expected that iQ3 will be realising further revenue, both in fees and equity, whilst contributing to Australia’s protagonistic role in the global life science arena.”
Further information will be released to the markets in due course as the program progresses.
For more information, please feel free to contact the iQ3Corp Investor Relations Team.
